Two headlines landed in the same week, and together they tell a much more useful story than either one on its own.

One was cautiously exciting: an oral tablet showed strong early results against relapsing MS. The other was sobering: an intensive cell-based immune therapy was paused across multiple trials after several patients died. Both stories are about "modulating the immune system." Both are aimed, in part, at the same culprit — B cells. And yet they sit at completely opposite ends of the intensity spectrum.

If you or someone you love lives with MS or another autoimmune condition, it's worth understanding why.

What actually happened

The advance: Novartis announced positive topline results from two Phase III trials of remibrutinib, an oral BTK inhibitor, in relapsing MS. Across roughly 2,000 participants in the REMODEL trials, the company reported it outperformed teriflunomide (an existing oral MS drug) on annualised relapse rate and inflammatory MRI lesions, with what it describes as a favourable safety profile and no identified liver safety signal.

The pause: In the same week, Novartis paused eight trials of its experimental CAR-T therapy, rapcabtagene autoleucel, in autoimmune and neurological conditions, after three patients died following a severe immune reaction. Bristol Myers Squibb paused studies of its own competing autoimmune CAR-T product after separate inflammatory events. The conditions under investigation span lupus, rheumatoid arthritis, vasculitis, MS and myasthenia gravis.

Why these are such different animals

Both approaches target B cells, the immune cells heavily implicated in MS and several systemic autoimmune diseases. But how they do it couldn't be more different.

BTK inhibitors work by interfering with a specific signalling pathway inside B cells and certain innate immune cells. Taken as a daily tablet, the appeal in MS is that a small molecule might be able to influence both circulating immune activity and inflammation within the nervous system itself — without wholesale elimination of immune cells.

CAR-T therapy is a different order of intervention entirely. A patient's own T cells are collected, genetically engineered to recognise a target — typically CD19 on the surface of B cells — and reinfused. The goal in severe autoimmunity is a deep enough B-cell depletion to produce something like an immune "reset." It's a powerful approach, adapted from blood cancer treatment, and it comes with correspondingly powerful risks: cytokine-release syndrome, neurotoxicity, and other severe immune reactions among them.

That's the heart of it — a treatment proven in blood cancer can't be assumed to carry an identical risk–benefit balance once it's applied to chronic autoimmune disease in a different patient population.

What's established, and what genuinely isn't yet

Established:

B cells contribute meaningfully to MS and several systemic autoimmune diseases.
B-cell-targeted therapies, broadly, can reduce disease activity.
CAR-T therapies carry real risk of cytokine-release syndrome, neurotoxicity and other severe immune reactions.
A treatment's safety profile in cancer doesn't automatically transfer to autoimmune disease.

Not yet established:

The true size of remibrutinib's clinical benefit — only topline figures have been released so far, and they come from the manufacturer.
Whether its benefits and safety profile hold up over long-term use.
Whether it will receive UK authorisation or a NICE recommendation.
Whether changes to monitoring or manufacturing could make rapcabtagene autoleucel acceptably safe going forward.
Whether CAR-T can ultimately deliver durable, drug-free remission across broader autoimmune populations.

The full remibrutinib dataset — absolute relapse rates, adverse events, detailed disability outcomes — isn't due until October. Until then, calling it a breakthrough, or safer than existing high-efficacy MS treatments, is getting ahead of the evidence. Equally, a trial pause is a serious safety signal, not proof that autoimmune CAR-T as a whole has failed.

The bigger picture

Phrases like "immune reset," "switching off autoimmunity," or "targeting neuroinflammation" can make it sound like there's one dial being turned up or down. In reality, immune regulation is not the same thing as immune suppression, and there's an enormous range of intervention within that spectrum — from a daily tablet nudging one signalling pathway, to a wholesale, engineered depletion of an entire immune cell lineage.

Every approach along that spectrum has to balance disease control against infection risk, inflammatory reaction, and the loss of protective immunity the body actually needs. None of it is as simple as "more suppression, less disease."

The take-home

A positive Phase III headline is not the same as having the complete trial data. And a trial pause for one experimental therapy doesn't mean the whole category has failed. Both stories, together, are a useful reminder that "immune modulation" isn't one thing — it's a whole spectrum, and where a treatment sits on it matters enormously.

If you're trying to understand how immune-related treatment decisions interact with your broader health and resilience, get in touch with The Goode Health Clinic — we work with you on our MS packages, alongside your specialist care.